NALTvsOxiracetam

NALT (N-acetyl L-tyrosine) is deacetylated by aryl acylamidase in the gut and liver to release L-Tyrosine. Tyrosine is hydroxylated to L-DOPA by tyrosine hydroxylase (TH) — the rate-limiting step in catecholamine synthesis, requiring tetrahydrobiopterin as cofactor. L-DOPA is decarboxylated by aromatic L-amino acid decarboxylase (AADC) to dopamine; dopamine is converted to norepinephrine by dopamine beta-hydroxylase (DBH), and norepinephrine to epinephrine by phenylethanolamine N-methyltransferase (PNMT). Under stress or sleep deprivation, catecholamine stores in noradrenergic and dopaminergic neurons deplete rapidly. Supplemental tyrosine provides substrate to maintain synthesis when demand exceeds supply, supporting prefrontal cortex function and working memory.

Oxiracetam enhances glutamatergic neurotransmission through positive allosteric modulation of AMPA receptors, increasing the amplitude and duration of excitatory postsynaptic potentials. It increases the release of excitatory neurotransmitters glutamate and D-aspartic acid from hippocampal presynaptic terminals, acting as a glutamate analog. Oxiracetam stimulates protein kinase C (PKC) isoforms, particularly PKC-α and PKC-γ, which phosphorylate substrates involved in memory consolidation, long-term potentiation (LTP), and synaptic plasticity. PKC activation enhances NMDA receptor function and AMPA receptor trafficking to the synapse. Its mild stimulatory effect derives from cholinergic system enhancement via increased acetylcholine release and nicotinic α7 receptor potentiation in the cortex.